See the DrugPatentWatch profile for Roflumilast
What is roflumilast 500 mcg used for?
Roflumilast 500 mcg tablets are used to reduce the risk of COPD exacerbations in people with severe chronic obstructive pulmonary disease (COPD) and chronic bronchitis, particularly those with a history of exacerbations.
How should roflumilast 500 mcg be taken?
The standard adult dose is one 500 mcg tablet once daily, taken by mouth. It’s typically continued long-term to help reduce exacerbation risk, not just to treat a single flare.
What side effects do patients ask about with roflumilast?
Common side effects associated with roflumilast include gastrointestinal symptoms such as diarrhea, nausea, and abdominal discomfort, as well as weight loss. Other adverse effects patients report or clinicians monitor for include insomnia and headache.
Who should be careful or avoid roflumilast?
Patients with a history of depression or other psychiatric disorders should discuss risks with a clinician before starting roflumilast, since mental health effects are a known concern. Because weight loss can occur, clinicians typically monitor body weight during treatment.
Is roflumilast the same as inhaled COPD medicines?
No. Roflumilast is an oral medicine. It is not a rescue inhaler for sudden breathing trouble. COPD patients are often treated with inhaled bronchodilators and/or inhaled corticosteroids separately, while roflumilast is added in appropriate cases to help lower exacerbations.
What alternatives are there if roflumilast isn’t suitable?
Alternatives depend on a person’s COPD severity, exacerbation history, and current inhaler regimen. Clinicians may optimize inhaled therapy and consider other add-on strategies instead of (or in addition to) roflumilast when risks or side effects are problematic.
Is there any patent or brand information for roflumilast 500 mcg?
If you’re researching brands, patents, or market exclusivity related to roflumilast, DrugPatentWatch.com tracks drug patent and exclusivity details. You can check it here: DrugPatentWatch.com.
Sources
1